Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Total Current Liabilities
All obligations due within one year.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 90.7% from a year ago
Total current liabilities stood at $17.9M at the end of Q1 FY2026, up 90.7% from a year earlier and down 6.0% from the prior quarter. Over 3 fiscal years it compounded at +125.4% a year.
Context
- Total current liabilities amounted to 3.6% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +90.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 19.05M USD
- Year-over-year change
- +117.3%
- 3-year CAGR
- +125.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.05M | +117.3% |
| FY2024 | 2024-12-31 | 8.77M | -0.4% |
| FY2023 | 2023-12-31 | 8.8M | +429.3% |
| FY2022 | 2022-12-31 | 1.66M | — |
Total Current Liabilities vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 total current liabilities of $17.9M is the 5th highest of the 10 companies compared; the peer median is $14.28M.
- Its year-over-year change of +90.7% is the 2nd highest of 10, against a peer median of +6.1%.
- Total current liabilities amounts to 3.6% of total assets for RAPP, versus a peer median of 4.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $460.45M | +34.6% | +57.7% | 60.5% | |
| Sep 2026 | $332.22M | -6.8% | +30.2% | 18.5% | |
| Sep 2026 | $52.5M | -0.7% | +20.3% | 4.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $30.12M | +6.1% | +11.0% | 19.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $17.9M | +90.7% | +125.4% | 3.6% |
| Mar 2026 | $14.28M | +10.0% | +8.8% | 3.4% | |
| Mar 2026 | $13.12M | +80.7% | +26.8% | 4.7% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $10.91M | +179.2% | +151.3% | 2.8% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $6.66M | -25.6% | +8.9% | 2.5% |
| Mar 2026 | $6.05M | -44.7% | +21.3% | 16.7% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $14.28M | +6.1% | +21.3% | 4.7% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.